Technical Analysis for GLSI - Greenwich LifeSciences, Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Up | Down | Up |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Crossed Above 20 DMA | Bullish | 6.82% | |
Inside Day | Range Contraction | 6.82% | |
Gapped Up | Strength | 6.82% | |
Fell Below 20 DMA | Bearish | 11.56% | |
Outside Day | Range Expansion | 5.96% | |
Spinning Top | Other | 4.00% | |
Crossed Above 20 DMA | Bullish | 6.58% | |
Pocket Pivot | Bullish Swing Setup | 6.58% | |
Wide Bands | Range Expansion | 6.58% | |
Fell Below 20 DMA | Bearish | 6.90% |
Alert | Time |
---|---|
Rose Above Previous Day's High | 32 minutes ago |
Down 1% | 32 minutes ago |
Upper Bollinger Band Resistance | 32 minutes ago |
10 DMA Support | 1 day ago |
Rose Above Previous Day's High | 1 day ago |
Get a Trading Sidekick!
- Earnings date: 05/22/2024
Greenwich LifeSciences, Inc. Description
Greenwich LifeSciences is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein. In a randomized, single-blinded, placebo-controlled, multi-center (16 sites led by MD Anderson Cancer Center) Phase IIb clinical trial, no recurrences were observed in the HER2/neu 3+ adjuvant setting after median 5 years of follow-up, if the patient received the 6 primary intradermal injections over the first 6 months (p = 0.0338). Of the 138 patients that have been treated with GP2 to date over 4 clinical trials, GP2 treatment was well tolerated and no serious adverse events were observed related to GP2 immunotherapy. Greenwich LifeSciences is planning to commence a Phase III clinical trial using a similar treatment regime as the Phase IIb clinical trial.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Clinical Medicine Acid Immunotherapy Surgery Cancer Treatment Breast Cancer Clinical Trial Treatment Of Breast Cancer Her2 Her2/Neu Cancer Center
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 21.44 |
52 Week Low | 7.58 |
Average Volume | 44,878 |
200-Day Moving Average | 11.35 |
50-Day Moving Average | 15.68 |
20-Day Moving Average | 13.33 |
10-Day Moving Average | 13.88 |
Average True Range | 1.13 |
RSI (14) | 54.34 |
ADX | 21.12 |
+DI | 20.33 |
-DI | 17.82 |
Chandelier Exit (Long, 3 ATRs) | 11.36 |
Chandelier Exit (Short, 3 ATRs) | 14.77 |
Upper Bollinger Bands | 14.78 |
Lower Bollinger Band | 11.89 |
Percent B (%b) | 0.99 |
BandWidth | 21.68 |
MACD Line | -0.29 |
MACD Signal Line | -0.49 |
MACD Histogram | 0.1934 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 16.42 | ||||
Resistance 3 (R3) | 16.24 | 15.49 | 16.14 | ||
Resistance 2 (R2) | 15.49 | 15.07 | 15.59 | 16.05 | |
Resistance 1 (R1) | 15.12 | 14.80 | 15.31 | 15.31 | 15.96 |
Pivot Point | 14.38 | 14.38 | 14.47 | 14.47 | 14.38 |
Support 1 (S1) | 14.01 | 13.95 | 14.19 | 14.19 | 13.54 |
Support 2 (S2) | 13.26 | 13.69 | 13.36 | 13.45 | |
Support 3 (S3) | 12.89 | 13.26 | 13.36 | ||
Support 4 (S4) | 13.08 |